DSIPvsIpamorelin

Delta Sleep-Inducing Peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite decades of research, its precise molecular receptor has not been definitively identified, making DSIP unusual among well-studied peptides. However, its physiological effects have been extensively characterized.

DSIP's sleep-promoting mechanism involves modulation of the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission in sleep-regulating brain regions. It enhances GABAergic tone in the ventrolateral preoptic area (VLPO) — the brain's primary sleep-promoting nucleus — while reducing glutamatergic excitatory drive in wake-promoting areas like the lateral hypothalamus and locus coeruleus. The net effect is promotion of slow-wave (delta) sleep, characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations. This is the deepest, most restorative sleep stage, during which growth hormone secretion peaks, memory consolidation occurs, and cellular repair processes are most active.

Beyond sleep, DSIP has significant neuroendocrine effects. It reduces cortisol secretion by suppressing corticotropin-releasing hormone (CRH) and ACTH release, lowering the activity of the hypothalamic-pituitary-adrenal (HPA) stress axis. This stress-reducing effect may itself contribute to sleep quality, as HPA axis hyperactivity is a common cause of insomnia and fragmented sleep. DSIP also modulates endogenous opioid signaling — it has been studied in opiate withdrawal protocols for its ability to normalize disturbed endorphin/enkephalin balance. Some research suggests it may regulate somatostatin release and interact with the orexin/hypocretin system, though these mechanisms are less well established. The paradox of DSIP is that despite its very short plasma half-life (15-25 minutes), sleep-promoting effects persist for hours, suggesting it triggers sustained changes in neural network activity or gene expression rather than requiring continuous receptor occupancy.

Ipamorelin is a pentapeptide growth hormone secretagogue that binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin activates. However, unlike ghrelin and other GHRPs such as GHRP-6 and Hexarelin, ipamorelin demonstrates remarkable selectivity — it stimulates robust GH release while causing minimal elevation of cortisol, prolactin, and ACTH at therapeutic doses.

At the molecular level, ipamorelin binding to GHS-R1a on pituitary somatotrophs activates a Gq/11-coupled signaling cascade that stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. The resulting rise in intracellular calcium triggers GH vesicle exocytosis. This mechanism is distinct from and synergistic with the cAMP pathway activated by GHRH, which is why combining ipamorelin with a GHRH analogue like CJC-1295 produces amplified GH pulses.

The selectivity of ipamorelin is attributed to its specific binding conformation at the GHS-R1a receptor, which activates the GH release pathway without engaging the broader hypothalamic-pituitary-adrenal axis. It does not significantly activate appetite centers in the hypothalamus at standard doses, nor does it stimulate ACTH release from corticotrophs. This clean side-effect profile has made it the most widely prescribed growth hormone secretagogue in anti-aging and regenerative medicine, often considered the safest starting point for patients new to GH-optimizing peptide therapy.